Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome.

Yuta Kojima Akiyuki UzawaYukiko OzawaManato YasudaYosuke OnishiHiroyuki AkamineNaoki KawaguchiKeiichi HimuroYu-Ichi NotoToshiki MizunoSatoshi Kuwabara

Published in: Journal of neurology, neurosurgery, and psychiatry (2021)

High RR-AChRAb is associated with a favourable outcome at 1-year post-treatment. AChR Ab remeasurement within 100 days of therapy may be useful for predicting AChR Ab-positive MG outcomes at 1-year post-treatment.

Keyphrases

myasthenia gravis
combination therapy
type diabetes
mesenchymal stem cells
skeletal muscle
bone marrow
binding protein
glycemic control